HOOK HOOKIPA Pharma Inc
Price (delayed)
$0.9167
Market cap
$11.05M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.47
Enterprise value
-$27.85M
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body's immune system.
Highlights
The debt has dropped by 87% year-on-year and by 69% since the previous quarter
The EPS has soared by 60% YoY and by 7% from the previous quarter
The revenue has soared by 118% YoY but it has decreased by 12% QoQ
HOOKIPA Pharma's gross profit has surged by 118% YoY but it has decreased by 12% QoQ
The company's equity fell by 43% YoY and by 29% QoQ
HOOK's quick ratio is down by 21% YoY and by 13% from the previous quarter
Key stats
What are the main financial stats of HOOK
Market
Valuations
Earnings
Shares outstanding
12.06M
Market cap
$11.05M
Enterprise value
-$27.85M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.22
Price to sales (P/S)
0.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.63
Revenue
$43.95M
Gross profit
$43.95M
Operating income
-$51.46M
Net income
-$43.5M
EBIT
-$43.61M
EBITDA
-$40.85M
Free cash flow
-$77.17M
Per share
Balance sheet
Liquidity
EPS
-$3.47
EPS diluted
-$3.47
Free cash flow per share
-$6.4
Book value per share
$4.25
Revenue per share
$3.65
TBVPS
$6.85
Total assets
$82.55M
Total liabilities
$31.33M
Debt
$875,000
Equity
$51.21M
Working capital
$56.01M
Debt to equity
0.02
Current ratio
3.27
Quick ratio
2.57
Net debt/EBITDA
0.95
Margins
Efficiency
Dividend
EBITDA margin
-93%
Gross margin
100%
Net margin
-99%
Operating margin
-117.1%
Return on assets
-37.6%
Return on equity
-55.5%
Return on invested capital
-178.2%
Return on capital employed
-75.3%
Return on sales
-99.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HOOK stock price
How has the HOOKIPA Pharma stock price performed over time
Intraday
-11%
1 week
-24.86%
1 month
-40.08%
1 year
-87.94%
YTD
-54.39%
QTD
-15.12%
Financial performance
How have HOOKIPA Pharma's revenue and profit performed over time
Revenue
$43.95M
Gross profit
$43.95M
Operating income
-$51.46M
Net income
-$43.5M
Gross margin
100%
Net margin
-99%
The revenue has soared by 118% YoY but it has decreased by 12% QoQ
HOOKIPA Pharma's gross profit has surged by 118% YoY but it has decreased by 12% QoQ
The net margin has surged by 76% year-on-year but it has declined by 14% since the previous quarter
The operating margin has surged by 76% year-on-year and by 3.9% since the previous quarter
Growth
What is HOOKIPA Pharma's growth rate over time
Valuation
What is HOOKIPA Pharma stock price valuation
P/E
N/A
P/B
0.22
P/S
0.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.63
The EPS has soared by 60% YoY and by 7% from the previous quarter
The P/B is 80% below the 5-year quarterly average of 1.2 and 60% below the last 4 quarters average of 0.6
The company's equity fell by 43% YoY and by 29% QoQ
The revenue has soared by 118% YoY but it has decreased by 12% QoQ
The price to sales (P/S) is 96% lower than the 5-year quarterly average of 7.0 and 72% lower than the last 4 quarters average of 1.0
Efficiency
How efficient is HOOKIPA Pharma business performance
The ROS has soared by 75% YoY but it has contracted by 15% from the previous quarter
The company's return on invested capital has surged by 69% YoY and by 9% QoQ
HOOKIPA Pharma's return on equity has increased by 35% YoY but it has decreased by 13% QoQ
The ROA is up by 22% YoY but it is down by 18% from the previous quarter
Dividends
What is HOOK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HOOK.
Financial health
How did HOOKIPA Pharma financials performed over time
The total assets is 163% more than the total liabilities
The total liabilities has dropped by 56% year-on-year and by 17% since the previous quarter
The total assets has contracted by 49% YoY and by 25% from the previous quarter
The debt is 98% smaller than the equity
The debt has dropped by 87% year-on-year and by 69% since the previous quarter
HOOKIPA Pharma's debt to equity has shrunk by 71% YoY and by 50% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.